Reunion Neuroscience Inc. — Reunion Neuroscience named Sahil V.
Kirpekar, M.D., as President and CEO and a board member, succeeding Greg Mayes. Kirpekar previously served as Chief Business Officer at atai Life Sciences (now AtaiBeckley), where he helped lead the acquisition of Beckley Psytech. He takes over as the privately held company advances luvesilocin (RE104), a short-duration psilocin-like prodrug that holds FDA Breakthrough Therapy Designation for postpartum depression, with Phase 2 trials underway in adjustment disorder and generalized anxiety disorder.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.